Intercure Ltd. — Regulatory Filings 2025

May 1, 2025

6-K 1 form6-k.htm 6-K

Field: Rule-Page

Field: /Rule-Page

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

Form 6-K

Report of Foreign Private Issuer

Pursuant to Rule 13a-16 or 15d-16

of the Securities Exchange Act of 1934

For the month of May 2025

Commission File Number: 001-40614

INTERCURE LTD.

(Translation of registrant’s name into English)

85 Medinat ha-Yehudim Street

Herzliya, 4676670, Israel

Tel: +972 77 460 5012

(Address of principal executive offices)

Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F.

Form 20-F ☒ Form 40-F ☐

Field: Rule-Page

Field: /Rule-Page

Field: Page; Sequence: 1

Field: /Page

On May 1, 2025, InterCure Ltd. issued a press release titled “InterCure Announces FY2024 Results and Provides Q1 2025 Update: Revenue of NIS 239 Million and Adjusted EBITDA of NIS 24 Million, Strong Start to 2025” a copy of which is furnished as Exhibit 99.1 with this report of foreign private issuer on Form 6-K.

| Exhibit
No. | |
| --- | --- |
| 99.1 | Press Release issued by InterCure Ltd. on May 1, 2025, titled “InterCure Announces FY2024 Results and Provides Q1 2025 Update: Revenue of NIS 239 Million and Adjusted EBITDA of NIS 24 Million, Strong Start to 2025.” |

Field: Page; Sequence: 2

Field: /Page

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

| | INTERCURE
LTD. |
| --- | --- |
| Date:
May 1, 2025 | /s/
Amos Cohen |
| | Amos
Cohen |
| | Chief
Financial Officer |

Field: Page; Sequence: 3; Options: Last

Field: /Page